A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

To join this study, you must be an adult aged 18 or older with a confirmed diagnosis of CIDP, or a type of CIDP such as motor CIDP or multifocal CIDP (also known as Lewis Sumner Syndrome). Your diagnosis will be re-checked by a special group of experts for the study.

You must also have responded well to IVIg treatment in the past five years and currently be receiving regular, stable IVIg doses. It's important that you still have some ongoing difficulties from your CIDP, even with IVIg, and that your condition shows some signs of being active. Your weight should be between 35 kg and 154 kg.

There are also some requirements about being up-to-date with certain vaccinations before starting the study medicine. If you are sexually active, you'll need to use effective contraception, and pregnant or breastfeeding individuals cannot take part. Men cannot donate sperm during the study. If you normally have IVIg at home, you'll need to switch to having it at a hospital or clinic before joining.

If you decide to take part, the study will last for up to 109 weeks, which is about two years. It starts with an initial check-up phase to ensure you meet all the requirements. You'll then go through different treatment phases where you might receive the new medicine (riliprubart), IVIg, or a placebo (a dummy treatment designed to look like the real thing but with no active medicine).

Throughout the study, you'll have regular visits to the clinic for assessments, which will include examinations, questionnaires about your symptoms and how you are feeling, and possibly blood tests. These checks help the study doctors understand how your condition is responding and monitor your health carefully. There will also be follow-up appointments after your main treatment period to ensure your wellbeing.